Update shared on04 Aug 2025
Fair value Increased 7.73%The upward revision in ResMed’s consensus price target reflects a modest increase in its future P/E multiple amid stable profit margins, resulting in a new fair value estimate of $289.71.
What's in the News
- Repurchased 419,000 shares for $100 million, completing 9,210,000 shares repurchased ($863.38 million) under the long-term buyback program.
- Declared a quarterly cash dividend of $0.60 per share, payable to shareholders of record in August.
- Expressed intention to pursue tuck-in acquisitions and continue investing in R&D and share buybacks.
- Dropped from the Russell 1000 Dynamic Index.
Valuation Changes
Summary of Valuation Changes for ResMed
- The Consensus Analyst Price Target has risen from $268.93 to $289.71.
- The Future P/E for ResMed has risen slightly from 26.96x to 27.84x.
- The Net Profit Margin for ResMed remained effectively unchanged, moving only marginally from 28.26% to 28.76%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.